CSE:ENBI - Post Discussion
Post by
Betteryear2 on Feb 27, 2022 3:58pm
Entheon Biomedical Announces EBIQ-101 First-Patient Dose
Vancouver, British Columbia--(Newsfile Corp. - February 24, 2022) - Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) (FSE: 1XU1) ("Entheon" or the "Company"), a biomedical company focused on the research and development of psychedelic drugs and leading-edge biomarkers to provide personalized treatment of addiction disorders, is pleased to provide an update on its Observational Study, EBIQ-101. Entheon Biomedical Announces EBIQ-101 First-Patient Dose
Be the first to comment on this post